MK-0767

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
MK-0767
Accession Number
DB12055
Type
Small Molecule
Groups
Investigational
Description

MK0767 has been used in trials studying the treatment of Dyslipidemia, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type II, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
MK 0767
Categories
UNII
Y180U02GSB
CAS number
934017-32-0
Weight
Average: 422.36
Monoisotopic: 422.108956144
Chemical Formula
C20H17F3N2O5
InChI Key
ORZMUVMQJPGFOM-UHFFFAOYSA-N
InChI
InChI=1S/C20H17F3N2O5/c1-29-15-7-4-12(9-16-18(27)25-19(28)30-16)8-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)
IUPAC Name
5-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-methoxy-N-{[4-(trifluoromethyl)phenyl]methyl}benzamide
SMILES
COC1=CC=C(CC2OC(=O)NC2=O)C=C1C(=O)NCC1=CC=C(C=C1)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
56842109
PubChem Substance
347828365
ChemSpider
32701664

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentMetabolic X Syndrome Dyslipidemia1
2TerminatedTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentDiabetes Mellitus1
3TerminatedTreatmentDyslipidemia / Type 2 Diabetes Mellitus1
3TerminatedTreatmentType 2 Diabetes Mellitus6

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00458 mg/mLALOGPS
logP2.53ALOGPS
logP3.02ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)6.63ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.73 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity99.23 m3·mol-1ChemAxon
Polarizability38.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-benzylbenzamides. These are compounds containing a benzamide moiety that is N-linked to a benzyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
N-benzylbenzamides
Alternative Parents
Trifluoromethylbenzenes / Anisoles / Benzoyl derivatives / Methoxybenzenes / Phenoxy compounds / Alkyl aryl ethers / Oxazolidinediones / Dicarboximides / Carbamate esters / Secondary carboxylic acid amides
show 8 more
Substituents
N-benzylbenzamide / Trifluoromethylbenzene / Phenoxy compound / Anisole / Benzoyl / Methoxybenzene / Phenol ether / Alkyl aryl ether / Oxazolidinedione / Oxazolidinone
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:16 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates